Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab Switch for RA Patients with Incomplete Etanercept Response
NCT00317538Phase 3Completed
- Sponsor
- Janssen Biotech
- Start
- Jun 2003
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of infliximab in rheumatoid arthritis (RA), sponsored by Janssen Biotech. Started Jun 2003; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00317538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317538.